Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...

Massachusetts gastrointestinal disease firm, Cristcot, has announced results from its Phase III trial examining its hydrocortisone suppository and applicator for ulcerative colitis (UC), finding it to ...

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical ...

FDA said the company's suppositories are not approved by the FDA and are misbranded because they do not bear adequate directions for use as required by law. The U.S. Department of Justice announced ...

CONCORD, Mass., Jan. 9, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, today announced positive topline results ...

AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company is ...